Posts in Category: Uncategorized

Cancer Center of America Provides Real Solutions with Clinical Pathways

The Cancer Treatment Centers of America recently collaborated with Allscripts to create a new solution that is going to create freedom for countless physicians. This new solution is going to help clinical flow with their work and not to mention give patients what they need to know regarding their future treatment options. The Clinical Pathways program is the new thing that they came up with, and now it is going to be used throughout the centers to give patients and physicians what they need. Clinical Pathways presents all the right treatment options that seem right for for the patient. It is going to help eliminate the questions regarding what is meant to be done for the patient since the physician will get every insight possible.

As stated on Wikipedia, Clinical Pathways integrates the best cancer research available to help you understand all aspects of what a patient must know about the treatment. Things like their overall health, what they need to watch out for, and anything about a treatment that could affect them are all explained in this new program.

With comparisons on all treatment options, custom treatment options updated based on their current disease and health states, and supporting data, you are sure to find the right solution to any problem or disease.

The Cancer Treatment Centers of America focuses primarily on providing adults with diseases the solutions and the help that they need. With five different hospitals nationwide and being based in Florida, they strive to provide the best service to adults that are in need of desperate help. This new type of technology that they have created is only going to help them focus more on how to deal with anything a person may deal with and what kind of treatment will work best with them both financially and also based on their body.

For further information follow CTCA on Facebook.

Oncologist Mikhail Blagosklonny Makes Valuable Contributions To The Field

Oncologist Mikhail Blagosklonny is an expert on cancer and aging. An oncology professor at New York based Roswell Park Cancer Institute has been doing research, writing and educating students and others interest in those two areas for decades. A graduate of the First Pavlov State Medical University of St. Peterburg, Blagosklonny has an M.D. in internal medicine as well as a PhD in cardiology and experimental medicine. He has also has more than 270 papers on cancer and aging published in well-respected peer-reviewed journals.

Blogosklonny is well-known for his valuable research on cancer and targeted therapies to treat the disease that protects healthy cells, biogerontology and the use and efficacy of anti-aging drugs. He has also come up with a hypothesis related to the role TOR signaling can play in cancer and aging and has proposed using the cancer drug rapamycin for life extension treatment. Blogosklonny is among the most passionate proponents of the use of rapamycin in longevity research. He is also the editor-in-chief of several popular publications dealing with cancer and aging including Oncotarget, Cell Cycle and Aging and Cancer Biology & Therapy’s associate editor. Blogosklonny is also a Cell Death & Differentiation editorial board member.

Appointed as a New York Medical College, Valhalla associate professor in 2002, Blogosklonny was then hired at Ordway Research Institute in Albany, New York as a senior scientist. He remained in that position until Roswell Park Cancer Institute hired him as professor of oncology in 2009. Blogosklonny is part of the institute’s Department of Cell Stress Biology. He has experience in Hematology, Clinical Trials,

Apoptosis, Signal Transduction, Phosphorylation, Protein Kinases, Protein Phosphorylation and Cancer Cell Biology. He has also done extensive work on Cell Proliferation, Cancer Cell Signaling, Tumor Biology, Senescence and Cancer Biomarkers.

Mikhail Blagosklonny also contributes to the blog Getting Stronger. It deals with the philosophy of Hormetism. That philosophy is based on the use of intermittent, progressive stress to help to overcome challenges as well as grow mentally, emotionally and physically stronger. Blogosklonny plays an important role in RPCI ability to provide superior and comprehensive education in several fields.

Biotechnology CEO Clay Siegall

Dr. Clay B. Siegall, Ph.D., co-founder of Seattle Genetics Inc., became its Chief Executive Officer in 2002. According to Bloomsberg, Dr. Siegall been involved in cancer research and related therapeutic drug development for more than 20 years.


Seattle Genetics is a biotechnology company that develops innovative antibody-based therapies that are used in cancer treatment. Currently, Seattle Genetics has only one commercialized drug, Adcetris, which fights lymphomas. However, the company has twelve more drugs under research and has hired 100 employees this year.


Most Glass Door reviews are favorable. Contributors call Seattle Genetics a great company with a small company feel and nice campus. Summer intern opportunities feature activities geared toward interns.



The George Washington Medicine and Health blog recently featured Siegall and reported that he became interested in oncology when his father was diagnosed with brain cancer. My mom was having a tough time. “Partway through my second year of grad school, my dad passed away,” he said.


As an ambitious student, he went on to earn a B.S. in Zoology at the University of Maryland and then he completed a Ph.D. in genetics at George Washington University. Siegall has worked with the Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute and the National Institutes of Health.


Siegall is listed in a Forbes blog, The Oprahs of Biotech, as one of a few industry leaders people know by first name alone.


Facebook searches for Siegall return a series of photo ops with Seattle Genetics employees at press releases celebrating the company’s accomplishments and grateful family members crediting his contributions to cancer research.